—— 要投稿,上万维,轻松学术交流

严正声明

本站非期刊官网,非中介代理,
不向作者收取任何费用!
举报微信:13140028228 冯老师

态度公正、信息求实、投稿自助、使用免费
The Journal of Clinical Pharmacology《临床药理学杂志》
月刊 - 美国
  • The Journal of Clinical Pharmacology《临床药理学杂志》
  • SCIE外文期刊
  • 期发文量15
  • 国人占比15.22%
  • 维普目次
  • 投稿方式--官网投稿
  • 期刊属性

  • 中科分区:4区
    OA期刊:混合
  • 综述期刊:
    TOP期刊:
  • 期均国文:2
    环比增速:0.00%
  • 期刊信息

  • 研究方向:医学-PHARMACOLOGY PHARMACY 药学
  • 国际刊号:ISSN0091-2700;EISSN1552-4604
  • 期刊语言:英语
    出版地区:美国
  • 投稿网址:http://mc.manuscriptcentral.com/jocp
  • 电子邮箱:
  • 期刊官网:https://accp1.onlinelibrary.wiley.com/journal/15524604
  • 作者指南:
  • 出版商网址:http://www.wiley.com/WileyCDA/
  • 出版地址:SAGE PUBLICATIONS INC, 2455 TELLER RD, THOUSAND OAKS, USA, CA, 91320
  • 期刊简介:The Journal of Clinical Pharmacology《临床药理学杂志》(月刊). The Journal of Clinical Pharmacology (JCP) is a Human Pharmacology journal designed to provide physicians, pharmacists, research scientists, regulatory scientists, drug developers and academic colleagues a forum to present research in all aspects of Clinical Pharmacology.

  • 万维提示


  • 1、投稿方式:在线投稿

    2期刊网址:

    https://accp1.onlinelibrary.wiley.com/journal/15524604

    3投稿网址:http://mc.manuscriptcentral.com/jocp

    4、官网邮箱:elizabeth.marshall@kwfco.com

    5、期刊刊期:月刊,一年出版12期。

    2021年8月20日星期

                                     

     

    投稿须知【官网信息】

     

    Author Guidelines

    Instructions for Authors

    Please visit The Journal of Clinical Pharmacology at http://accp1.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)1552-4604/author-guidelines.html to reach these instructions at any time.

    For guidance on how to prepare, write and submit a manuscript to any journal, please follow this link: http://www.mpip-initiative.org/mpip-authorship-activities/authors-submission-toolkit

    Page Charges: JCP has no page charges for publication.

    Please Note: These instructions must be followed for manuscript submission to JCP. Manuscripts will be returned without review if the instructions are not followed.

    Editorial Content

    JCP is a publication dedicated to clinical (human) pharmacology. Manuscripts are invited that deal with the effects of drugs in humans. Animal research and in vitro research without direct human applicability will not be considered. These include, but are not limited to, the general categories of pharmacokinetics (PK) and drug disposition, drug metabolism, pharmacodynamics (PD), clinical trials and design issues, pharmacogenomics and pharmacogenetics, pharmacometrics and population PK/PD, pharmacoepidemiology, pharmacovigilence, and human pharmacology. In addition, another area of emphasis for submissions is the validation and use of biomarkers in drug development. Articles should be clearly written and well organized. Priority will be given to new developments in the field along with manuscripts dealing with PK/PD relationships of drug response in humans.

    Types of Papers (The limits should be strictly followed)

    Original Research Papers (Full Manuscript)

    These may be up to 6500 words, 8 tables/figures total and up to 150 references. An unstructured abstract is required.

    Original Research Papers (Brief Report)

    These may be up to 3250 words, 4 tables/figures total and up to 75 references. An unstructured abstract is required.

    Reviews

    Both narrative and systematic reviews are considered for publication. All narrative reviews must critically evaluate the literature and should not cite other reviews in the reference list. Reviews that are just a restatement of the literature will be rejected. Additionally, all reviews must have tables and/or figures and not be solely text. Reviews may be up to 7000 words, 10 tables/figures total, and up to 200 references. An unstructured abstract is required.

    Reporting on Meta-Analyses

    All meta-analyses to be published in the Journal should have clear objectives regarding drug effects and be based on thorough, systematic and recent review of the literature. Usually, a meta-analysis is done to determine the general and more specific effects on the basis of various small or large studies investigating the same research questions. The search strategy, selection process and statistical methods used should be described in detail in the manuscript. Beyond the type and design of selected studies, authors should provide details on exposure regarding the drug(s) to be examined, i.e., substance, dose, route of administration, and duration of treatment. Relevant patient characteristics, e.g.,. demographics, disease state and co-medication, should be described in sufficient detail. Meta-analysis of clinical trials should be accompanied by the PRISMA flow diagram and checklist (LIberati et al., PLoS Med. 2009 Jul 21;6(7):e1000100), those of observational studies of clinical trials should be accompanied by the MOOSE checklist (Stroup et al., JAMA. 2000; 283(15):2008-12). The preferred length of meta-analyses is as described above for original research papers. Extensive tables on the characteristics of included or excluded studies should be submitted as Electronic Supplementary Material (ESM) (for detailed information on ESM see also Electronic Supplementary Material in the Instructions for Authors) and will be published online only. Meta-analyses reports should follow the guidelines for Full Manuscript Original Research Papers.

    ……

    更多详情:

    https://accp1.onlinelibrary.wiley.com/hub/journal/15524604/author-guidelines







欢迎点评!让信息更透明,使投稿更轻松!
  • 审稿时间:
    是否录用:
  • 见刊周期:
    查重要求:
  • 有无课题:
    有无回复:
  • 我的学历:
    我的职称:
  • 审稿费用:
    版面费用:
  • 稿       费:
    稿件字数:
  • 投稿难度:
  • 该刊可发:
  • 投稿主题:
匿名: 验证码: 点击切换验证码
    评分:0

    验证码: 点击切换验证码